Introduction
============

Aldo-keto reductases (*AKRs*) form a superfamily of proteins characterised by their common three-dimensional structure and reaction mechanism in catalysing the reduced nicotinamide adenine dinucleotide (phosphate) (NAD(P)H)-dependent oxido-reduction of carbonyl groups.\[[@B1],[@B2]\] More than 150 enzymes have been identified in a wide range of organisms, including prokaryotes and eukaryotes such as plants, fungi and vertebrates. Based on sequence identity, the proteins fall into 15 different families, termed AKR1-AKR15, and some families (eg AKR1) contain multiple subfamilies.\[[@B1],[@B3],[@B4]\] Fourteen human *AKRs*(Table [1](#T1){ref-type="table"}), which fall into families 1, 6 and 7, have been annotated and their specific structural and kinetic features, as well as substrate and genomic characteristics, have been recently and comprehensively reviewed.\[[@B5],[@B6]\]

*AKRs*are, for the most part, cytosolic and are active as monomers. So far, only AKR2, AKR6 and AKR7 family members show evidence of forming multimers, although it is unclear whether quaternary structure is essential for enzyme activity.\[[@B7]-[@B9]\] The single amino acid chain of, on average, 320 residues folds into a (α/β)~8~-barrel, an evolutionarily highly conserved structure originally observed in triose-phosphate isomerase (TIM) and therefore also known as a TIM barrel structure. In contrast to another 32 superfamilies adopting this motif, *AKRs*do not require metal ions for functionality, and bind NAD(P)H cofactor in an extended anti-conformation so that they can catalyse 4-pro-R hydride transfer and thus belong to the large group of A-face oxidoreductases.

###### 

Systematic and trivial names of human Aldo-keto reductases (*AKRs*)

  Systematic name   Trivial name/often-used abbreviations
  ----------------- ---------------------------------------------------------------------------------------------
  AKR1A1            Aldehyde reductase; ALR; ALDR1
  AKR1B1            Aldose reductase; AR, ALR2
  AKR1B10           Small intestine-like aldose reductase; ARL-1
  AKR1C1            Dihydrodiol dehydrogenase I; 20α,(3α)-Hydroxysteroid dehydrogenase
  AKR1C2            Dihydrodiol dehydrogenase 2; 3α-Hydroxysteroid dehydrogenase, type III
  AKR1C3            3α-Hydroxysteroid dehydrogenase, type II
  AKR1C4            Dihydrodiol dehydrogenase 4; chlordecone reductase; 3α-hydroxysteroid dehydrogenase, type I
  AKR1D1            Δ^4^-3-Ketosteroid-5β-reductase
  AKR1E2            Aldo-keto reductase family I, member C-like 2; AKRICL2
  AKR6A3            KCNAB I; hKvbeta3; potassium voltage-gated channel, shaker-related subfamily, β-member 1
  AKR6A5            KCNAB 2; hKvbeta2; potassium voltage-gated channel, shaker-related subfamily, β-member 2
  AKR6A9            KCNAB 3; potassium voltage-gated channel, shaker-related subfamily, β-member 3
  AKR7A2            Aflatoxin aldehyde reductase; AFAR1
  AKR7A3            Aflatoxin aldehyde reductase; AFAR2

The spectrum of AKR substrates is wide and comprises aldehydes, ketones, monosaccharides, ketosteroids, ketoprostaglandins, bile acid precursors, chemical carcinogens and their metabolites \-- for example, aflatoxin dialdehydes, nicotine-derived 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and *trans*-dihydrodiols of polycyclic aromatic hydrocarbons. Substrate recognition and binding takes place at the C-terminal end of the ellipsoid (α/β)~8~-barrel body through interaction with amino acids within the three highly variable loops pro-2 10 11 truding out of the barrel structure. \[[@B2],[@B10],[@B11]\] Indeed, sequence conservation among *AKRs*is lowest in these loops, compared with the α-helices and β-strands forming the barrel structure itself, and suggests that *AKRs*evolved from a common ancestor by duplication and subsequent divergence to accommodate the binding of the structurally diverse substrates.

Duplication and diversification indeed seem to have been the driving force in the formation of vertebrate *AKRs*. AKR1B, AKR1C and AKR7A family members appear to be vertebrate specific and in the human genome their genes cluster on chromosomes 7, 10 and 1, respectively.\[[@B5]\] Furthermore, the potential of these three subfamilies to give rise to new functional *AKRs*is reflected in the existence of several pseudogenes and putative new isoforms in the human genome. By contrast, the genes of all three human AKR6 family members reside in different chromosomal locations, show a high degree of conservation, even to plant AKR6 isoforms, and do not give rise to functional or non-functional (pseudogene) gene duplications.

Biochemistry of *AKRs*
======================

Almost all *AKRs*catalyse the reduction of aldehydes and ketones to primary and secondary alcohols, respectively, by use of a reduced nicotinamide cofactor. The reactions involve an ordered bi-bi kinetic mechanism and general acid-base catalysis.\[[@B12]-[@B14]\] The cofactor binds first, followed by tethering of the substrate. In the reduction direction, the 4-pro-*R*hydride from NAD(P)H is transferred to the substrate carbonyl group, followed by protonation of the carbonyl oxygen by a conserved tyrosine acting as a general acid.\[[@B15]-[@B17]\] Oxidation proceeds in the reverse sequence with the tyrosine acting as a general base.

Asp 50, Tyr 55, Lys 84 and His 117 form the catalytic tetrad (based on residue numbering in AKR1C9),\[[@B2],[@B18],[@B19]\] where the Tyr is the general acid-base.\[[@B17],[@B20]\] Conservation of these residues is strong and underlines their role in catalysis. Asp 50 is present in 99 per cent, Tyr 55 in 97 per cent, Lys 84 in 97 per cent and His 117 in 88 per cent of all annotated *AKRs*on the AKR website. Consistent substitution of these key amino acids, however, especially of the histidine, is a characteristic for some AKR subfamilies. In AKR1D isoforms, which catalyse the 5β-reduction of Δ^4^-3-ketosteroids, glutamate replaces His 117.\[[@B2],[@B21]\] Interestingly, muta-tional analysis in AKR1C9 demonstrates that this single amino acid substitution is sufficient to convert this 3-ketosteroid reductase to a steroid 5β double-bond reductase.\[[@B22],[@B23]\] The reverse change of function has been hypothesised for the respective (E120H) mutation in AKR1D1.\[[@B24]\] In all AKR6A isoforms, the conserved histidine is changed to asparagine. Based on crystal structure comparisons, Di Costanzo et al. hypothesised that in AKR6A isoforms the amino acid in this position is involved in substrate discrimination.\[[@B25]\] AKR6A isoforms, better known as voltage-gated potassium channel (β-subunits (Kvβ or KCNAB), accept a wide range of substrates, but their catalytic efficiency is significantly lower than other *AKRs*.\[[@B26],[@B27]\] It has been suggested that they may primarily function as redox state sensors in the regulation of potassium channel activity.\[[@B27]-[@B29]\] The replacement ofhistidine with asparagine may provide more space to allow for the optimal positioning of bulky lipid and phospholipid aldehydes, formed as products oflipid peroxidation and oxidative stress.

Although these four conserved amino acids seem to play a crucial role in the catalytic mechanism, targeted mutation studies (eg in AKR1B1\[[@B15]\] and AKR1C9\[[@B30]\]) did not indicate a complete loss in enzymatic activity and suggested that, in some instances, proximity of the hydride donor to the acceptor is sufficient to catalyse a reaction. Furthermore, some *AKRs*, such as ρ-crystallins in amphibian lenses (AKR1C10), appear to have been employed in this tissue basically for structural reasons, having lost almost all enzymatic activity despite unaltered characteristics of the cofactor and substrate binding site.\[[@B31]\]

Nomenclature
============

The nomenclature for the AKR superfamily, introduced and accepted by the Hugo Genome Nomenclature Committee (HGNC) in 1997, builds solely on sequence and not on functional similarity. Furthermore, systematic annotation through the AKR website requires proof of functionality of the protein in question. This evidence may be RNA or enzyme based, and aims to avoid the annotation of non-functional pseudogenes or predicted genes of unknown physiological function. Sequence submission for the assignment of a systematic AKR superfamily name should be sent directly to the AKR website (<http://www.med.upenn.edu/akr/>).\[[@B3],[@B4]\] The basic principle in naming a new AKR follows that for the cytochrome P (CYP) superfamily \[[@B32],[@B33]\]. All members of the super-family are annotated with the suffix AKR. The 15 families (Figure [1](#F1){ref-type="fig"}) into which annotated *AKRs*fall have less than 40 per cent amino acid identity with each other. Subfamilies, denoted by a capital roman letter, share up to 60 per cent sequence identity. Individual members in the subfamily are numbered according to the chronology of sequence submission to the AKR website. Thus, AKR1A1 (human aldehyde reductase) belongs to family 1, subfamily A and is the first unique protein in the subfamily. If two sequences share 97 per cent or more sequence identity, they are considered as alleles and marked by an additional small roman letter (eg AKR1C10a and AKR1C10b). Two sequences sharing this high degree of identity are not regarded as alleles if they reside in different genomic locations, have distinct 3\' untranslated regions or differ in their enzymatic activities. It was also recommended that the corresponding gene be given the same name as the protein, but written in italics.

![**Dendogram of all systemically annotated AKR enzymes**. All sub-trees comprising more than a single member have been collapsed and the width of the resulting wedge reflects the number of annotated sequences in this category. Circled capital letters denote the species of origin A, archeae; B, bacteria; E, ecdysozoa; F, fungi; P, plants; T, trypanosomatidae; V, vertebrate.](1479-7364-3-4-362-1){#F1}

The nomenclature has the advantage that it assigns a unique gene name to each single AKR through establishing its amino acid sequence similarity to other families and subfamilies. In this way, it is independent of enzyme properties, species of origin and functional homologies. Therefore, it is not surprising that most families at the same time constitute clusters of closely related organisms rather than similar function, and that an AKR of a more distantly related organism will fall into a different subfamily (Figure [1](#F1){ref-type="fig"}). For example, bacterial *AKRs*form their own families with multiple subfamilies owing to the high diversification that has occurred in the 3,900 million years since bacteria and archeae split. At the same time, vertebrate, but especially mammalian, AKR sequences (mammalians appeared about 300 million years ago) form sequence clusters with multiple, highly similar members in each subfamily. Inspection of the vertebrate AKR sequences reveals that the AKR1 family evolved separately from families AKR6 and AKR7. Furthermore, only potassium channel β-subunit sequences have been so well conserved during evolution that plant and arthropod sequences both cluster in the AKR6 family.

A search for *AKRs*on NCBI, HGNC and Ensembl
============================================

Although the new nomenclature came into effect nearly 12 years ago\--and has been widely accepted by the AKR research community\--it has not yet become widely adopted by database annotators. This is especially true for non-mammalian *AKRs*. Of the 160 proteins annotated on the AKR website (<http://www.med.upenn.edu/akr/>), 62 give problematic results if searched with their systematic name against the National Center for Biotechnology Information (NCBI) database. For 45 *AKRs*, not a single database entry can be found. This illustrates that regular updates of protein and nucleotide annotations have failed to notice and acknowledge the proposed systematic nomenclature.

Annotation and nomenclature of human *AKRs*, however, are far more consistent. A database search for human *AKRs*at the National Institutes of Health (<http://www.ncbi.nlm.nih.gov>), the European Molecular Biology Laboratory (<http://www.ensembl.org>), the Sanger Institute (<http://vega.sanger.ac.uk/index.html>) and the HGNC (<http://www.genenames.org>) identified 13 of the 14 proteins listed on the AKR website (Table [1](#T1){ref-type="table"}). AKR1E2, which appears in all four databases under its synonym AKR1CL2, was originally annotated as LoopADR in 2000 and later named AKR1C like 2 (AKR1CL2), based on its sequence similarity to AKR1C isoforms. In 2003 and 2004, two publications described the enzymatic activity of this protein towards 9,10-phenanthrenequinone, but not steroid hormones, and termed it human testis-specific AKR (htAKR), based on its restricted expression pattern.\[[@B34],[@B35]\] The protein shares 74 per cent sequence identity with the previously described murine AKR1E1\[[@B36]\] and hence was systematically named AKR1E2.

Unclassified and predicted human AKR database entries
=====================================================

The database search for human *AKRs*at NCBI also revealed a number of other sequences annotated in context with *AKRs*. The total of 58 database entries comprised the 14 systematically annotated and well-described human *AKRs*and 12 separate annotations of pseudogenes. The search also revealed that in 22 cases, the respective protein belonged to a different protein family but appears in a biological context with an AKR. The remaining ten database entries (Table [2](#T2){ref-type="table"}) resemble unclassified or predicted human AKR sequences that are related to three different AKR subfamilies: AKR1C, AKR1B and AKR7A.

*AKR1CL1*is located between *AKR1C3*and *AKR1C4*on chromosome 10. Ambiguous reports at NCBI describe two different forms of the gene. In one case, exons 1-4 of eight exons encode a 129-amino acid peptide (Accession No. NP001007537.1). This protein includes the complete catalytic tetrad but appears to be too short to be a functional AKR. In the second case, *AKR1CL1*, similarly to the other four *AKR1C*members, consists ofnine exons and encodes a complete 326-amino acid protein (Accession No. EAW86451) with 68 per cent sequence identity to AKR1C1-4. The shorter version exactly matches residues 1-129 of the longer form and resembles a differently transcribed and processed version of the same gene. A few messenger RNA (mRNA) sequences are annotated that match *AKR1CL1*with deletions and frameshifts, but a Blast search with the longer version against the expressed sequence tag (EST) database does not yield any *AKR1CL1*transcripts. Therefore, it remains unclear whether *AKR1CL1*is a processed pseudogene or a new functional AKR1C member.

###### 

Non-classified human *AKRs*in the NCBI database

  Name             Alternative names   **Gene ID**^a^   Chromosomal location   Related to   Probable identity
  ---------------- ------------------- ---------------- ---------------------- ------------ ------------------------------------------
  *AKR1B1I*        *ARL, HSI*          9405             7                      AKR1B        Variance of AKR1B10
  *AKR1B10L*       *tcag7.1260*        441282           7q33                   AKR1B        New AKR or pseudogene of AKR1B10
  *LOC340888*                          340888           10q2l.3                AKR1B        Retro-transposed *AKR1B10*pseudogene
  *LOC643582*                          643582           I8q22.l                AKR1B        Retro-transposed *AKR1B10*pseudogene
  *AKR1CL1*        *RAKc*              340811           10pI5.I                AKR1C        New *AKR1C*or pseudogene
  *AKR1C-pseudo*                       266745           10pI5-10pI4            AKR1C        *Variance*of AKR1C2
  *LOC6485I7*                          648517           Unclear                AKR1C        AKR1C *pseudogene or transcript variant*
  *LOC100I34257*                       100134257        Unclear                AKR1C        AKR1C *pseudogene or transcript variant*
  *LOC643789*                          643789           10pI5.I                AKR1C        Pseudogene
  *LOC648947*                          648947           10pI5.I                AKR1C        AKR1CL1 *pseudogene*
  *tAKR*                               389932           10pI5.I                AKR1C        AKR1C *pseudogene*
  *AKR7L*          *AKR7A4, AFAR3*     246181           Ip35-Ip36.I            AKR7A        New *AKR7A*or pseudogene
  *AFARPI*                             246182           IpI2                   AKR7A        Retro-transposed *AKR7*pseudogene

^a^At NCBI (<http://www.ncbi.nlm.nih.gov>).

*AKRlC-pseudo*is an old, discontinued entry that resembles *AKR1C2*. AKR1C2 shares 97 per cent sequence identity with AKR1C1 but exhibits a unique expression pattern and substrate specificity.\[[@B37]-[@B41]\]*LOC648517*and *LOC100134257*contain sequence elements that completely match exons of *AKR1C1*and *AKR1C2*. Their chromosomal location could not be determined, however, and therefore it is not clear whether they might be transcript variants of either *AKR1C1*or *AKR1C2*, or are separate pseudogenes.

Four entries are related to AKR1B10. While *AKR1B11*is a discontinued record replaced by *AKR1B10*, *LOC340888*and *LOC643582*are Gnomon predictions and appear to be retrotransposed pseudogenes of *AKR1B10*. *AKR1B10L*resides next to *AKR1B10*on chromosome 7 and also consists of ten exons. The two proteins share 91 per cent amino acid identity. The presence of a single EST from placenta (BX350113.2) that completely matches residues 23-209 of the predicted 316-amino acid AKR1B10L transcript suggests that AKR1B10L could indeed resemble a new and thus far uncharacterised human AKR family member. Alternatively, the presence of the mRNA could result from a processed pseudogene.

Two additional database entries relate to the *AKR7*family. *AKR7L*clusters together with *AKR7A2*and *AKR7A3*on chromosome 1p35-1p36.1.\[[@B3],[@B42]\] Alternative transcription leads to two different transcript variants. Variant 1 is the longer and comprises seven exons that encode a 331-amino acid protein. This form may indeed resemble a new functional AKR that has 92 per cent and 88 per cent identity with AKR7A3 and AKR7A2, respectively. Variant 2 lacks exons 4 and 5 and codes for a probably non-functional alternative peptide. This deletion results in a frameshift-eliminating sequence similarity to *AKRs*in the last 80 amino acids of the 250-amino acid peptide. The *AKR7*family pseudogene (*AFARP1*)isaretro-transposed *AKR7*, where the complete processed mRNA has reintegrated into the genome.

In addition, Barski et al.\[[@B5]\] report on three putative *AKRs*not identified in the above-described database search. The database entry *LOC643789*was originally designated as the *AKR1C*pseudo-gene but was discontinued in March 2008. *LOC648947*is a predicted gene with nine exons, encodes a 316-amino acid protein and shares 82 per cent sequence identity with the longer version of AKR1CL1; however, this protein sequence harbours a stop codon following amino acid 199. At least three mRNA sequences for this gene are present in the EST database. They do not completely match the predicted protein sequence of *LOC648947*, and a region corresponding to amino acids 192-227 is deleted. As this deletion covers a region conserved in all AKR1C isoforms, it is very likely that *LOC648947*represents a processed pseudogene of *AKR1CL1*. Finally, tAKR shows similarity to other AKR1C isoforms and the gene is located between *AKR1CL2*and *AKR1C1*on chromosome 10. Original annotation predicts a gene of 11 exons, with exons 3-11 encoding a putative protein with more than 300 amino acids. A transcript exists only for the first 125 amino acids, however, and hence *tAKR*is thus far classified as a processed pseudogene.

In summary, systematic integration of these AKR database entries into the AKR nomenclature is still pending owing to a lack of sufficient experimental data to support an assignment.

Annotated variants of *AKRs*
============================

Efforts have been made systematically to describe genetic variants and splice isoforms in annotated human *AKRs*and to identify the location and classification of putative pseudogenes (Table [3](#T3){ref-type="table"}). Data on single nucleotide polymorphisms (SNPs) are accumulating rapidly, and the SNP database build 130 (NCBI), as of 30th April 2009, contains over 17.8 million SNP clusters, with over 7.3 million SNPs located in genes. Nomenclature for SNPs in *AKRs*is based on that for sulfotransferase (SULT) genes\[[@B43]\] and takes only coding SNPs into account.\[[@B4]\] Systematic annotation of the SNP is marked by the gene name followed by an asterisk, an Arabic number indicating synonymous (\'1\') or non-synonymous (\'2\'-\'n\') character and a letter distinguishing between suballeles; the nomenclature is chronologically based. While this seems to be a feasible approach for synonymous and non-synonymous SNPs, it neglects SNPs leading to fra-meshifts and those in the non-coding gene region that have the potential to alter the transcription efficiency, splicing and stability of mRNA. For all *AKRs*SNP frequency is significantly higher than the estimated 1 SNP/kilobase.\[[@B44],[@B45]\] Although the total number of SNPs per gene is only a snapshot in this time of extremely rapid data growth, it appears that some *AKRs*(eg *AKR1D1*, *AKR6A3*and *AKR6A9*) have accumulated significantly fewer single nucleotide variations in their coding region than others.

###### 

Genomic and transcriptomic variations in annotated human *AKRs*

  AKR      Gene ID^a^   Chromosomal location   No. of SNPs^b^(in gene/coding region/non-synonymous/frameshift)   SNP frequency (per 1 kilobase: in gene/in coding region)   Peptide variants   Additional processed transcripts   Pseudogenes on vega (HGNC)
  -------- ------------ ---------------------- ----------------------------------------------------------------- ---------------------------------------------------------- ------------------ ---------------------------------- ----------------------------
  *1A1*    10327        1p33-p32               154/9/5/1                                                         8.01/9.2                                                   3                  10                                 0
  *1B1*    231          7q35                   160/13/9/0                                                        9.53/13.67                                                 3                  12                                 5(8)
  *1B10*   57016        7q33                   127/16/5/0                                                        9.65/16.82                                                 1                  3                                  4
  *1C1*    1645         10p15-p14              160/16/6/0                                                        10.88/16.46                                                3                  2                                  0
  *1C2*    1646         10p15-p14              353/16/8/0                                                        12.5/16.46                                                 1                  1                                  0
  *1C3*    8644         10p15-p14              261/23/13/2                                                       19.61/23.66                                                1                  3                                  0
  *1C4*    1109         10p15 -p14             198/7/6/0                                                         8.95/7.2                                                   1                  1                                  0
  *1D1*    6718         7q32-q33               275/1/0/0                                                         6.57/1.02                                                  4                  2                                  2(1)
  *1E2*    83592        10p15.1                211/12/7/0                                                        9.66/12.46                                                 2                  4                                  0
  *6A3*    7881         3q26.1                 1888/1/0/0                                                        4.51/0.81                                                  10                 0                                  0
  *6A5*    8514         1p36.3                 414/8/2/1                                                         7.15/7.25                                                  8                  6                                  0
  *6A9*    9196         17p13.1                42/3/1/2                                                          6.24/2.47                                                  1                  2                                  0
  *7A2*    8574         1p36.13                71/10/8/0                                                         8.68/9.26                                                  1                  0                                  4
  *7A3*    22977        1p36.13                67/12/5/0                                                         10.76/12.05                                                1                  0                                  0

^a^At NCBI (<http://www.ncbi.nlm.nih.gov>).

^b^Deduced from the vega database (<http://vega.sanger.ac.uk/index.html>).

The table does not include the putative transcript variants and pseudogenes listed in Table [2](#T2){ref-type="table"}.

In addition to SNPs, other variations have been annotated over the years. The most well known are pseudogenes, and one or several have been identified for a few *AKRs*. For example, the pseudogene forms of *AKR1B1*are well documented and systematically annotated as *AKR1B1P1-8*, where P stands for pseudogene. For example, *AKR1B1P4*denotes the fourth pseudogene annotated for *AKR1B1*. Analysis of the non-systematically named *AKRs*(Table [2](#T2){ref-type="table"}) suggests that many more pseudogenes, in addition to the few already annotated, might exist. This may also bethecaseforalternativespliceforms, wherethe vega database (<http://vega.sanger.ac.uk/index.html>) from the Sanger Institute offers the most systematic annotation approach. Gene transcripts are numbered in the order of their annotation and designated with the suffix \'-n\' added to the specific gene name. For example, *AKR1C1*has five different transcripts, annotated as *AKR1C1-001*to *AKR1C1-005*. For half of the human *AKRs*, transcript processing leads to one or more alternative peptides. Furthermore, non-coding RNAs have been identified for 11 of the 14 genes. While, in the past, these fragments have been ignored, being perceived as resulting from errors in transcription or splicing, increasing evidence suggests that they play important regulatory functions (eg in gene expression, imprinting, RNA stability, splicing and translation).\[[@B46]\] Their role in AKR expression and function remains to be elucidated.

Summary
=======

Proteins of the AKR superfamily are present in all phyla and are characterised by their common three-dimensional structure and reaction mechanism. Fourteen human *AKRs*have so far been annotated with systematic gene names in accordance with a systematic nomenclature provided through the AKR website that is based on amino acid sequence similarity and proof of protein functionality. Additional non-systematic annotations of human *AKRs*are present in the NCBI database that may resemble new, uncharacterised proteins or pseudogenes of existing *AKRs*. Furthermore, the rapid and continuous increase in data on SNPs and transcript variants challenges a systematic annotation of these phenomena and adds to the complexity of defining the functionality of a given gene product. Despite these complexities, the AKR website provides the most comprehensive and up-to-date portal for tracking the development of AKR annotation and provides links to in-depth information on each single AKR superfamily member in other databases.
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